Bicyclic quinazolinone derivatives

Abstract

wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R12, R13, R14, A1, A2, A3, n and m are as described herein.

1 - 42 . (canceled) 
     
     
         43 . A compound, wherein the compound is:
 (3R)-3-[[2-[6-(4-acetylpiperazin-1-yl)-4-oxoquinazolin-3-yl]acetyl]amino]-N-benzyl-3-[4-(trifluoromethyl)phenyl]propanamide;   2-[6-(4-acetylpiperazin-1-yl)-2,4-dioxo-1H-quinazolin-3-yl]-N-[(3,4-dichlorophenyl)methyl]acetamide;   2-[6-(4-acetylpiperazin-1-yl)-4-oxoquinazolin-3-yl]-N-[2-(3,4-dichlorophenyl)ethyl]acetamide;   2-[6-(4-acetylpiperazin-1-yl)-4-oxoquinazolin-3-yl]-N-[[3-(4-chlorophenyl)-1,2-oxazol-5-yl]methyl]acetamide; or   2-[6-(4-acetylpiperazin-1-yl)-4-oxoquinazolin-3-yl]-N-[[5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl]methyl]acetamide;   or a pharmaceutically acceptable salt thereof.   
     
     
         44 . The compound of  claim 43 , wherein the compound is (3R)-3-[[2-[6-(4-acetylpiperazin-1-yl)-4-oxoquinazolin-3-yl]acetyl]amino]-N-benzyl-3-[4-(trifluoromethyl)phenyl]propanamide, or a pharmaceutically acceptable salt thereof. 
     
     
         45 . The compound of  claim 43 , wherein the compound is 2-[6-(4-acetylpiperazin-1-yl)-2,4-dioxo-1H-quinazolin-3-yl]-N-[(3,4-dichlorophenyl)methyl]acetamide, or a pharmaceutically acceptable salt thereof. 
     
     
         46 . The compound of  claim 43 , wherein the compound is 2-[6-(4-acetylpiperazin-1-yl)-4-oxoquinazolin-3-yl]-N-[2-(3,4-dichlorophenyl)ethyl]acetamide, or a pharmaceutically acceptable salt thereof. 
     
     
         47 . The compound of  claim 43 , wherein the compound is 2-[6-(4-acetylpiperazin-1-yl)-4-oxoquinazolin-3-yl]-N-[[3-(4-chlorophenyl)-1,2-oxazol-5-yl]methyl]acetamide, or a pharmaceutically acceptable salt thereof. 
     
     
         48 . The compound of  claim 43 , wherein the compound is 2-[6-(4-acetylpiperazin-1-yl)-4-oxoquinazolin-3-yl]-N-[[5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl]methyl]acetamide, or a pharmaceutically acceptable salt thereof. 
     
     
         49 . A pharmaceutical composition, comprising a compound according to  claim 43 , or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier. 
     
     
         50 . A method for the treatment of a condition, comprising administering a compound according to  claim 43 , or a pharmaceutically acceptable salt thereof,
 wherein the condition is selected from the group consisting of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, conditions of the respiratory system, vascular and cardiovascular conditions, fibrotic diseases, cancer, ocular conditions, metabolic conditions, cholestatic and other forms of chronic pruritus, and acute and chronic organ transplant rejection.   
     
     
         51 . The method of  claim 45 , wherein the condition is an ocular condition. 
     
     
         52 . The method of  claim 46 , wherein the ocular condition is proliferative retinopathy, non-proliferative diabetic retinopathy, dry age-related macular degeneration, wet age-related macular degeneration, macular edema, central arterial occlusion, central venous occlusion, traumatic injury, or glaucoma. 
     
     
         53 . The method of  claim 47 , wherein the condition is glaucoma.